Actinium Pharmaceuticals Announces Successful Completion of Planned Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed/Refractory AML at Medical College of Wisconsin Sep 14, 2020
Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual H.C. Wainwright Global Investor Conference Sep 10, 2020
Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares Apr 24, 2020
Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020 Apr 16, 2020
